Qiagen and Celera establish distribution agreement for respiratory pathogen panel
Qiagen and Celera have announced an agreement under which Qiagen will distribute a Celera molecular multiplex assay. The assay is the next generation version of Qiagen’s ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run.
Under the terms of the agreement, Qiagen has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.
The new ResPlex kits will be available through Qiagen’s existing sales channels. The new test will be submitted for regulatory approval in the United States and Europe.
DKSH brings Bioyond Robotics' lab automation products Down Under
DKSH will provide distribution of the Bioyond Robotics portfolio of AI-driven autonomous...
Immunologist wins GSK Award for respiratory virus research
Award winner Professor Katherine Kedzierska seeks to answer an important question: why do some...
ATSE names Jane O'Dwyer as its new CEO
O'Dwyer is an executive leader with more than 30 years' experience across higher...
